Stem cell factor, interleukin-16, and interleukin-2 receptor alpha are predictive biomarkers for delayed and slow graft function

Transplantation Proceedings

Volumn 42, Issue 9, 2010, Pages 3399-3405

  Alachkar, N ^a   Ugarte, R ^a   Huang, E ^a   Womer, K L ^a   Montgomery, R ^a   Kraus, E ^a   Rabb, H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; BIOLOGICAL MARKER; CREATININE; DACLIZUMAB; INTERLEUKIN 16; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; MONOCYTE CHEMOTACTIC PROTEIN 3; MYCOPHENOLIC ACID; STEM CELL FACTOR; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT DYSFUNCTION; HUMAN; KIDNEY GRAFT REJECTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SLOW GRAFT FUNCTION; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BALTIMORE; BIOLOGICAL MARKERS; DELAYED GRAFT FUNCTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-16; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPERFUSION INJURY; STEM CELL FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649479451     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.06.013     Document Type: Article

References (40)

1. T.A.F. El-Maghraby, H. Boom, and J.A.J. Camps Delayed graft function is characterized by reduced functional mass measured by (99m)Technetium- mercaptoacetyltriglycine renography Transplantation 74 2002 203
2. E. Rodrigo, J.C. Ruiz, and C. Piera Creatinine reduction ratio on post-transplant day two as criterion in defining delayed graft function Am J Transplant 4 2004 1163
3. E. Keite, T. Michelon, and A.F. dos Santos Renal transplants using expanded cadaver donor criteria Ann Transplant 9 2004 23
4. M. Giral-Classe, M. Hourmant, and D. Cantarovich Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys Kidney Int 54 1998 972
5. A.J. McLaren, W. Jassem, and D.W. Gray Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation Clin Transplant 13 1999 266
6. A. Humar, T. Ramcharan, and R. Kandaswamy Risk factors for slow graft function after kidney transplants: a multivariate analysis Clin Transplant 16 2002 425
7. O. Johnston, P. O'kelly, and S. Spencer Reduced graft function (with or without dialysis) vs immediate graft function-a comparison of long-term renal allograft survival Nephrol Dial Transplant 21 2006 2270
8. M. Pérez Fontn, A. Rodrquez-Carmona, and P. Bouza Outcome of grafts with long-lasting delayed function after renal transplantation Transplantation 62 1996 42
9. R. Marcn, J. Pascual, and L. Orofino The effect of delayed graft function and early graft rejection on renal transplant outcome Transplant Proc 30 1998 1776
10. D. Linfert, T. Chowdhry, and H. Rabb Lymphocytes and ischemia-reperfusion injury Transplant Rev 23 2009 1
11. S.G. Coca, and C.R. Parikh Urinary biomarkers for acute kidney injury: perspectives on translation Clin J Am Soc Nephrol 3 2008 481
12. R. Oberbauer Biomarkers-a potential route for improved diagnosis and management of ongoing renal damage Transplant Proc 40 2008 S44
13. K. Murphy, P. Travers, and M. Walport Janeway's Immunobiology 7th Ed. 2007 Garland Pub 783
14. T.R. Malek, A. Yu, and L. Zhu IL-2 family of cytokines in T regulatory cell development and homeostasis J Clin Immunol 28 2008 635
15. S.J. Greenberg, L. Marcon, and B.J. Hurwitz Elevated levels of soluble interleukin-2 receptors in multiple sclerosis N Engl J Med 319 1988 1019
16. P. Gallo, M.G. Piccinno, and S. Pagni Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid J Neurol Sci 92 1989 9
17. H.P. Kim, J. Imbert, and W.J. Leonard Both integrated and differential regulation of components of the IL-2/IL-2 receptor system Cytokine Growth Factor Rev 17 2006 349
18. A.C. Makis, E. Galanakis, and E.C. Hatzimichael Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis J Infect 51 2005 206
19. C. Giordano, A. Galluzzo, and A. Marco Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients Diabetes Res 8 1988 135
20. K. Adachi, T. Kumamoto, and S. Araki Interleukin-2 receptor levels indicating relapse in multiple sclerosis Lancet 1 1989 559
21. F. Casiraghi, P. Ruggenenti, and M. Noris Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction Transplantation 63 1997 1508
22. C.R. Parikh, A. Jani, and V.Y. Melnikov Urinary interleukin-18 is a marker of human acute tubular necrosis Am J Kidney Dis 43 2004 405
23. C.R. Parikh, A. Jani, and J. Mishra Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation Am J Transplant 6 2006 1639
24. I.E. Hall, S.G. Yarlagadda, and S.G. Coca IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation J Am Soc Nephrol 21 2009 189
25. S.C. Clark, and R. Kamen The human hematopoietic colony-stimulating factors Science 236 1987 1229
26. S. Wang, H. Diao, and Q. Guan Decreased renal ischemia-reperfusion injury by IL-16 inactivation Kidney Int 73 2008 318
27. M.M. El Kossi, J.L. Haylor, and T.S. Johnson Stem cell factor in a rat model of serum nephrotoxic nephritis Nephron Exp Nephrol 108 2008 e1
28. A.F. El-Koraie, N.M. Baddour, and A.G. Adam Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides Kidney Int 60 2001 167
29. S. Bengatta, C. Arnould, and E. Letavernier MMP9 and SCF protect from apoptosis in acute kidney injury J Am Soc Nephrol 20 2009 787
30. H. Liu, F. Liu, and Y. Peng Role of mast cells, stem cell factor and protease- activated receptor-2 in tubulointerstitial lesions in IgA nephropathy Inflamm Res 59 2010 551
31. J. Van Damme, P. Proost, and J.P. Lenaerts Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family J Exp Med 176 1992 59
32. D.D. Taub, P. Proost, and W.J. Murphy Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes J Clin Invest 95 1995 1370
33. P. Allavena, G. Bianchi, and D. Zhou Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3 Eur J Immunol 24 1994 3233
34. C. Tsou, W. Peters, and Y. Si Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites J Clin Invest 117 2007 902
35. A. Hiraoka, A. Sugimura, and T. Seki Cloning, expression, and characterization of a cDNA encoding a novel human growth factor for primitive hematopoietic progenitor cells Proc Natl Acad Sci U S A 94 1997 7577
36. C. Ito, H. Sato, and K. Ando Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation Bone Marrow Transplant 32 2003 391
37. J. Domnguez, F. Lira, and P. Troncoso Factors that predict duration of delayed graft function in cadaveric kidney transplantation Transplant Proc 41 2009 2668
38. S.J. Patel, B.T. Duhart, and A.G. Krauss Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction Transplantation 86 2008 313
39. J. Jushinskis, S. Trushkov, and J. Bicans Risk factors for the development of delayed graft function in deceased donor renal transplants Transplant Proc 41 2009 746
40. M.C. Warl, C.L.S.S. Cheung, and S. Teerenstra Cold ischaemia time and outcome of renal transplantation Ned Tijdschr Geneeskd 154 2010 B539